SAN DIEGO, Oct. 26, 2023 Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and.
B-Cell Lymphoma Clinical Trial Pipeline Insights | 160+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research report report published on Saturday. The brokerage issued a sell rating on the stock. A number of other analysts also recently commented on ONCT. Cantor Fitzgerald restated a neutral rating and issued a $1.30 target price on shares of Oncternal […]
Shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Free Report) have received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target […]
StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note issued to investors on Friday morning. The firm issued a sell rating on the stock. Several other analysts also recently commented on the company. HC Wainwright upgraded Oncternal Therapeutics from a neutral rating to a buy rating and set […]